mRNA therapy for primary ciliary dyskinesia(Translate Bio)

N/A

Report date: 2025/01/26 16:19:30
NME

Base Information

Drug NamemRNA therapy for primary ciliary dyskinesia(Translate Bio)
Drug Alias NameDNAI1-LNP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionDNAI1 protein expression stimulants
TargetsDynein axonemal intermediate chain 1
Therapy Area/IndicationsKartagener Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTranslate Bio Ma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTranslate Bio Ma Inc
Inactive CompaniesN/A
Active IndicationsKartagener Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A